Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.
It has been announced that Celgene, a biotechnology company, has signed an agreement to buy Receptos for $7.2 billion. This will result in a boost for its inflammation and immunology portfolio.
Celgene and Bristol-Myers Squibb have founded a clinical trial alliance for a potential new cancer combination therapy. As part of the alliance, the two companies will conduct a Phase I clinical study to assess the safety, tolerability and early efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo and Celgene’s chemotherapy Abraxane.
The Scottish Medicines Consortium (SMC) has approved Celgene’s Vidaza (azacitidine) in patients with advanced myelodysplastic syndromes (MDS). The SMC’s decision takes into account benefits of a new patient access scheme for Vidaza, which is the only drug available in Europe for advanced myelodysplastic syndrome, a rare but debilitating disease which affects around 2,150 people in